Q-linea Builds Global Momentum on Expanded ASTar Panel and Leaner Cost Base

Q-linea AB ( (SE:QLINEA) ) has issued an update.

Q-linea reported first-quarter 2026 results marked by a 60% rise in consumables revenue to SEK 1.4 million, a narrower operating loss of SEK 35 million, and successful implementation of a restructuring program expected to deliver annual savings of about SEK 16 million. Despite modest net sales of SEK 2 million and negative cash flow, recurring revenue from consumables grew as the installed base expanded, with record shipment volumes in March and a transition to fully in-house consumables production lowering cost of goods sold.

Commercial momentum accelerated around the recent U.S. FDA clearance of an expanded ASTar panel, which now offers the most comprehensive rapid phenotypic AST menu on the market with significantly more drug–bug combinations than competitors. New contracts and evaluations across the U.S., Italy, Austria, the Gulf region, and emerging markets such as Ukraine, Vietnam, and South Asia signal strengthening global demand, while the company’s leaner cost base and strong pipeline, particularly in the U.S., position it for increased placements and higher consumables usage through the second half of 2026.

More about Q-linea AB

Q-linea AB is a Swedish diagnostics company focused on rapid phenotypic antimicrobial susceptibility testing (AST) for hospitals and clinical laboratories. Its flagship ASTar system targets bloodstream and other severe infections, offering high-throughput, automated testing designed to combat antimicrobial resistance and support faster, more accurate antibiotic treatment decisions in markets across the U.S., Europe, and the Middle East.

YTD Price Performance: -27.63%

Average Trading Volume: 9,123

Technical Sentiment Signal: Sell

Current Market Cap: SEK336.1M

For an in-depth examination of QLINEA stock, go to TipRanks’ Overview page.